is retatrutide a glp 1 agonist review of an investigational drug retatrutide, a novel triple agent for the treatment of obesity | European Journal of Clinical Pharmacology Cagrilintide vs Retatrutide Compared |

However, the use of this medication requires a prolonged initial treatment period of dose-escalation to attenuate the adverse gastrointestinal effects (nausea, vomiting, diarrhea) typically associated with GLP-1R agonists, which still occurred frequently but rarely resulted in discontinuation of treatment

USA 89 , 48454849 (1992)

While weight loss effects generally transition from rodents to humans, the maximum efficacy is typically two to four times lower in humans compared to rodents

Providers consider whether the patient has tried each medication individually, the degree of weight loss achieved, tolerance of side effects, and reasons for considering combination therapy